Clinical trials: Anaplastic Thyroid Carcinoma
Thyroid Cancer
Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer
The aims of this trial are to evaluate the efficacy and tolerability of pemetrexed + paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer.
- Trial name
- Panthera (NCT00786552)
- Testing
- pemetrexed + paclitaxel
- Where
- Germany
- Volunteers
- 47 people
- Sponsor
- University Hospital Schleswig-Holstein
Thyroid Cancer
PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer
The purpose of this study is to evaluate the efficacy and safety of PD-1 inhibitor and anlotinib combined with multimodal radiotherapy for the second-line treatment of recurrent or metastatic anaplastic thyroid cancer.
- Trial name
- NCT05659186
- Testing
- Tislelizumab, Anlotinib, Radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Anaplastic Thyroid Carcinoma, Thyroid Cancer
Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer
This study is a single institution non-randomized phase 2 trial looking at the effect of Pulsed Stereotactic Ablative Radiotherapy (PULSAR) followed by neoadjuvant chemotherapy dabrafenib and trametinib (DT) with or without…
- Conditions
- Anaplastic Thyroid Carcinoma, Thyroid Cancer, Thyroid Carcinoma
- Trial name
- NCT07886905
- Testing
- Dabrafenib, Trametinib, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Washington University School of Medicine
Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
This phase II trial studies how well inolitazone dihydrochloride (efatutazone dihydrochloride) and paclitaxel work in treating patients with anaplastic thyroid cancer that has spread to other places in the body and usually cannot…
- Trial name
- NCT02152137
- Testing
- efatutazone, paclitaxel
- Where
- 253 sites in United States
- Volunteers
- 19 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Thyroid Cancer
Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer
The purpose of this Phase 2 study is to find out what effect, good and/or bad, external beam radiation therapy, has on the patient and their thyroid cancer where surgery is not an option or where despite surgery, the disease is…
- Trial name
- NCT01882816
- Testing
- IMRT, DWI MRI, Doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anaplastic Thyroid Cancer
interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
Anaplastic thyroid cancer has historically proven very difficult to research due to a combination of its rarity and the associated short survival period for those affected.
- Trial name
- iNATT (NCT01774279)
- Testing
- Tissue, blood and clinical data collection
- Where
- 15 sites in Ireland, United Kingdom
- Volunteers
- 350 people
- Sponsor
- Velindre NHS Trust
Thyroid Cancer
Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3
Although thyroid cancers are low-grade endocrine malignancy, most patients usually received thyroidectomy with ablative radioactive iodine therapy.
- Trial name
- NCT03488134
- Where
- Taiwan
- Volunteers
- 74 people
- Sponsor
- National Taiwan University Hospital
Anaplastic Thyroid Cancer
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
The Phase I/II study will be conducted as an open label, multiple center study of CS-7017, an experimental drug and paclitaxel chemotherapy in subjects with advanced anaplastic thyroid cancer.
- Trial name
- NCT00603941
- Testing
- CS-7017, Paclitaxel
- Where
- 10 sites in United States
- Volunteers
- 19 people
- Sponsor
- Daiichi Sankyo
Anaplastic Thyroid Cancer
Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
The purpose of the study is to determine the safety and efficacy of combretastatin combined with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).
- Trial name
- FACT (NCT00507429)
- Testing
- CA4P, paclitaxel, carboplatin
- Where
- 41 sites in United States, Belarus and 10 more
- Volunteers
- 80 people
- Sponsor
- Mateon Therapeutics
Bone Sarcoma, Dedifferentiated Chondrosarcoma
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer…
- Conditions
- Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone
- Trial name
- NCT03449108
- Testing
- Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00077103
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Case Comprehensive Cancer Center
Cancer
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
This was a Phase II, open-label, non-randomized, multi-center study of oral dabrafenib in combination with oral trametinib in subjects with rare cancers harboring the BRAF V600E mutation including anaplastic thyroid cancer (ATC)…
- Trial name
- NCT02034110
- Testing
- Dabrafenib, Trametinib
- Where
- 41 sites in United States, Austria and 12 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Renal Cell Carcinoma (RCC), Lung Cancer
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CD70-targeted CAR-T cell preparations, and to preliminarily observe the study drug in…
- Conditions
- Renal Cell Carcinoma (RCC), Lung Cancer, Anaplastic Thyroid Carcinomas, Ovarian Cancer
- Trial name
- NCT07181720
- Testing
- CD70-targeted CAR-T cells
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Anaplastic Thyroid Cancer
Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)
There are currently no target therapies approved for treatment of anaplastic thyroid cancer (ATC), leading to a clear need for improving therapy for ATC.
- Trial name
- NCT04574817
- Testing
- HX008
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
This phase II trial studies how well atezolizumab in combination with chemotherapy works in treating patients with anaplastic or poorly differentiated thyroid cancer.
- Conditions
- Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8
- Trial name
- NCT03181100
- Testing
- Atezolizumab, Bevacizumab, Cobimetinib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Anaplastic Thyroid Cancer, Thyroid Cancer
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF…
- Conditions
- Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors
- Trial name
- NEO-COMBATXL (NCT06902376)
- Testing
- Cemiplimab, XL092
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Thyroid Carcinoma, Thyroid Cancer
European Multicenter Study on Surgical Management of Advanced Thyroid Cancer
The main aim of the study is to evaluate peri-operative surgical characteristics, operation extent, postoperative morbidity, and outcomes in patients undergoing surgery for advanced thyroid cancer in different European centers…
- Conditions
- Thyroid Carcinoma, Thyroid Cancer, Thyroid Neoplasms, Thyroid Cancer, Papillary
- Trial name
- ATCEU (NCT05796960)
- Testing
- Thyroidectomy with or without lymphadenectomy or multivisceral resection
- Where
- Italy
- Volunteers
- 3,917 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Anaplastic Thyroid Cancer
NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
Anaplastic thyroid cancer (ATC) is an almost invariable lethal cancer in humans. Most patients present with a rapid progressive mass in the neck with progressive complaints like dyspnoea, dysphagia or pain.
- Trial name
- NEO-ATACT (NCT06079333)
- Testing
- dabrafenib/trametinib
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Leiden University Medical Center
Anaplastic Thyroid Cancer, Thyroid Cancer
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
This research study is a phase I/II study of MLN0128 in metastatic anaplastic thyroid cancer(ATC) and incurably poorly differentiated or radioidodine refractory differentiated thyroid cancer (DTC).
- Conditions
- Anaplastic Thyroid Cancer, Thyroid Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT02244463
- Testing
- MLN0128
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Dana-Farber Cancer Institute